Product Recalls
Recall of Rosart HCT Film Coated Tablets 50mg/12.5mg and Rosart HCT Film Coated Tablets 100mg/25mg
Audiences
Healthcare professional
Product type
Therapeutic Products
13 May 2022
Retail-level recall of several batches of Rosart HCT Film Coated Tablets 50mg/12.5mg and Rosart HCT Film Coated Tablets 100mg/25mg, containing losartan, due to impurity above acceptable level.
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
Recall details
Date of recall: | 13 May 2022 |
|---|---|
Product: |
|
Active Ingredient: | Losartan Potassium |
Product Category: | Therapeutic product |
Batch No.: | Please refer to Annex for the batch numbers |
Class of Recall: | 2 |
Level of Recall: | Retail |
Local Company: | Ranbaxy (Malaysia) Sdn. Bhd. |
Description of Issue: | During recent testing, an impurity, 5-[4’-[(5-(azido methyl)-2-butyl-4-chloro-1H-imidazol-1-yl) methyl]-[1,1’-biphenyl]-2-yl]-1H-tetrazole, was found to be above the acceptable level in several batches of Rosart HCT Film Coated Tablets 50mg/12.5mg and Rosart HCT Film Coated Tablets 100mg/25mg. As a precautionary measure, the affected batches are recalled. |
Recall Instructions: | Hospitals, clinics, pharmacies: Stop supplying the affected batch and return the remaining stocks to the company. |
Annex
List of affected batches
Product Name | Batch Number |
|---|---|
Rosart HCT Film Coated Tablets 50mg/12.5mg | AB55977 |
Rosart HCT Film Coated Tablets 50mg/12.5mg | DFC0294A |
Rosart HCT Film Coated Tablets 50mg/12.5mg | DFC1392A |
Rosart HCT Film Coated Tablets 50mg/12.5mg | DFC1394A |
Rosart HCT Film Coated Tablets 50mg/12.5mg | DFC2337A |
Rosart HCT Film Coated Tablets 100mg/25mg | AB55976 |
Rosart HCT Film Coated Tablets 100mg/25mg | DFC0295A |
Rosart HCT Film Coated Tablets 100mg/25mg | DFC1391A |
Rosart HCT Film Coated Tablets 100mg/25mg | DFC1393A |
Rosart HCT Film Coated Tablets 100mg/25mg | DFC2338A |
Note:
The Health Sciences Authority (HSA) publishes information regarding recalls of health products supplied in Singapore. These product recalls may be conducted on a company’s own initiative or upon HSA request to remove products where there are issues with quality, safety or efficacy.
When a recall is initiated, it does not necessarily imply that a product is considered unsafe or is inefficacious. A recall can also be initiated to remove products with quality defects that does not impact safety or efficacy from the market so as to ensure that products registered in Singapore continue to meet the stringent regulatory standards stipulated by HSA.
Not all recalls will lead to press releases. However, when a recall involves a product that has been widely distributed or a product that poses a serious health risk, HSA will issue a press release to inform members of public.
Class of recall
A recall is classified as Class 1 or Class 2 depending on the potential hazard of the issue.
Class 1: For recalls of products with issues that can potentially cause serious adverse health outcomes or death.
Class 2: For recalls of products with issues that would not likely cause serious adverse health outcomes.
Level of recall
The level of product recall will depend on the potential hazard of the affected product, extent of distribution and whether other mitigating measures can be taken to address the issue.
Consumer level: Affected product or batch(es) recalled from patients and consumers as well as wholesale suppliers, retail suppliers, hospitals, clinics and pharmacies.
Retail level: Affected product or batch(es) recalled from retail suppliers, hospitals, clinics and pharmacies as well as wholesale suppliers.
Wholesale level: Affected product or batch(es) recalled from wholesale suppliers.